Exhibit 10.12 SEVERANCE AGREEMENT This SEVERANCE AGREEMENT (this "Agreement"), made as of the 28th day of May 1996 (the "Effective Date"), by and between T CELL SCIENCES, INC., a Massachusetts corporation with its main office in Needham, Massachusetts...Severance Agreement • March 26th, 1997 • T Cell Sciences Inc • In vitro & in vivo diagnostic substances • Massachusetts
OPTION AGREEMENTOption Agreement • June 1st, 1998 • T Cell Sciences Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 99.3 SECURITIES PURCHASE AGREEMENT DATED AS OF JULY 13, 2000Securities Purchase Agreement • August 7th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
Exhibit 10.6 Dear : The Board of Directors (the "Board") of T Cell Sciences, Inc. (the "Company") has determined that appropriate steps should be taken to reinforce and encourage the continued attention and dedication of members of the Company's...Change in Control Agreement • March 28th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
WITNESSETHConsulting Agreement • March 26th, 1997 • T Cell Sciences Inc • In vitro & in vivo diagnostic substances • Massachusetts
Exhibit 4.1 ------------------- STOCK PURCHASE AGREEMENT THIS AGREEMENT is made as of the day of March, 1998, between T Cell Sciences, Inc. (the "Company"), a corporation organized under the laws of the State of Delaware with its principal offices at...Stock Purchase Agreement • June 12th, 1998 • T Cell Sciences Inc • In vitro & in vivo diagnostic substances • Massachusetts
Exhibit 99.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT is made as of July 13, 2000, by and among Avant Immunotherapeutics, Inc., a Delaware corporation (the "Company"), and the Persons set forth on Schedule I attached hereto...Registration Rights Agreement • August 7th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
STOCK PURCHASE AGREEMENT DATED DECEMBER 1, 2000 BY AND BETWEEN AVANT IMMUNOTHERAPEUTICS, INC.Stock Purchase Agreement • March 27th, 2001 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
Exhibit 10.15Settlement Agreement • March 30th, 1998 • T Cell Sciences Inc • In vitro & in vivo diagnostic substances • Massachusetts
CELLDEX THERAPEUTICS, INC. 8,520,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • March 1st, 2024 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 8,520,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 8,520,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,278,000 Shares pursuant to such option collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Leerink Partners LLC and Cowen and Company, LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as used herein shall mean Le
ANDSecurities Purchase Agreement • October 20th, 1999 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New York
WITNESSETHEmployment Agreement • July 16th, 1998 • T Cell Sciences Inc • In vitro & in vivo diagnostic substances • Massachusetts
Exhibit 10.7 CONSULTING AGREEMENT THIS AGREEMENT, dated this 1st of January 1997, between DR. PATRICK C. KUNG, residing at 5 Joseph Comee Road, Lexington, Massachusetts 02173 (the "Consultant"), and T CELL SCIENCES, INC., with its headquarters at 119...Consulting Agreement • March 26th, 1997 • T Cell Sciences Inc • In vitro & in vivo diagnostic substances • Massachusetts
RECITALSLicense Agreement • March 28th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
CELLDEX THERAPEUTICS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • February 26th, 2024 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
AMENDMENT TO LEASE BETWEEN MOULTON REALTY COMPANY AND VIRUS RESEARCH INSTITUTE, INC.Lease • March 28th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
PRICING AGREEMENT Roth Capital Partners. LLC 24 Corporate Plaza Newport Beach, CA 92660Pricing Agreement • February 23rd, 2004 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
AGREEMENT BETWEENConfidentiality Agreement • March 27th, 2001 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • England
EXHIBIT 10.20 LICENSE AGREEMENT This License Agreement ("Agreement") is made effective as of this first day of December 1997, between VIRUS RESEARCH INSTITUTE, Inc., having a place of business at 61 Moulton Street, Cambridge, MA 02138, USA (herein...License Agreement • March 28th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
WITNESSETH:License Agreement • March 28th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Ohio
WITNESSETHEmployment Agreement • March 25th, 1999 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
BETWEENAsset Purchase Agreement • March 20th, 1996 • T Cell Sciences Inc • In vitro & in vivo diagnostic substances • Massachusetts
EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGERMerger Agreement • December 12th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Delaware
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • July 1st, 2021 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Delaware
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of July 1, 2021 (the “Effective Date”), between Diane Young, MD (the “Executive”) and CELLDEX THERAPEUTICS, INC., a Delaware corporation (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”).
AVANT IMMUNOTHERAPEUTICS, INC. AND EQUISERVE TRUST COMPANY, N.A. AS RIGHTS AGENT SHAREHOLDER RIGHTS AGREEMENT DATED AS OF NOVEMBER 5, 2004Shareholder Rights Agreement • November 8th, 2004 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Delaware
Agreement, dated as of November 5, 2004, between AVANT Immunotherapeutics, Inc., a Delaware corporation (the "Company"), and EquiServe Trust Company, N.A., a national trust company (the "Rights Agent").
AMENDMENT TO RIGHTS AGREEMENT 1. GENERAL BACKGROUND. In accordance with Supplements and Amendments Section of the Rights Agreement between State Street Bank and Trust Company (the "Rights Agent") and Avant Immunotherapeutics, Inc. ("AVANT...Rights Agreement • March 27th, 2002 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
INCENTIVE STOCK OPTION GRANT AGREEMENT CELLDEX THERAPEUTICS, INC.Incentive Stock Option Grant Agreement • June 17th, 2021 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”).
RECITALSLicense Agreement • March 28th, 2000 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
7,000,000 Shares Celldex Therapeutics, Inc. Common Stock, $0.001 Par Value per Share UNDERWRITING AGREEMENTUnderwriting Agreement • December 5th, 2013 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
NONQUALIFIED STOCK OPTION GRANT AGREEMENT CELLDEX THERAPEUTICS, INC.Nonqualified Stock Option Grant Agreement • June 17th, 2021 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 6th, 2011 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Maryland
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of December 30, 2010 (the “Effective Date”) among MIDCAP FINANCIAL, LLC, a Delaware limited liability company, with an office located at 7735 Old Georgetown Road, Suite 400, Bethesda, Maryland 20814 (“MidCap”), as collateral agent (“Agent”), the Lenders listed on Schedule 1.1 hereof and otherwise party hereto from time to time (each a “Lender” and collectively, the “Lenders”), CELLDEX THERAPEUTICS, INC., a Delaware corporation (“Celldex”) and CELLDEX RESEARCH CORPORATION, a Delaware corporation (“Celldex Research”; Celldex and Celldex Research are referred to herein individually and collectively, jointly and severally, as “Borrower”) provides the terms on which Lenders shall lend to Borrower and Borrower shall repay Lenders. The parties agree as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 2nd, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New York
This Registration Rights Agreement (this "Agreement") is made and entered into as of July 1, 2003, by and among AVANT Immunotherapeutics, Inc., a Delaware corporation (the "Company"), and the investors signatory hereto (each a "Purchaser" and collectively, the "Purchasers").
EMPLOYMENT AGREEMENTEmployment Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into this 5th day of April 2006 (the “Effective Date”), between DR. THOMAS DAVIS, whose principal residence is located at 6275 Firethorn Lane, Clarksville, Maryland 21029 (the “Executive”), and CELLDEX THERAPEUTICS, INC., with its principal place of business located at 222 Cameron Drive, Suite 400, Phillipsburg, New Jersey 08865 (the “Company”) (collectively, the Executive and the Company shall be referred to as the “Parties”). In consideration of the mutual promises and agreements contained herein, the Parties agree as follows:
EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT February 13, 2004 Roth Capital Partners, LLC 24 Corporate Plaza Newport Beach, CA 92660 Ladies and Gentlemen: INTRODUCTORY. AVANT Immunotherapeutics, Inc., a Delaware corporation (the "Company"), proposes,...Placement Agency Agreement • February 23rd, 2004 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • California
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. THIRD AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • March 7th, 2018 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Connecticut
THIS THIRD AMENDED AND RESTATED LICENSE AGREEMENT (this “AGREEMENT”), dated as of March 14, 2013 (the “THIRD AMENDMENT EFFECTIVE DATE”), by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and KOLLTAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, and with principal offices located at 300 George Street, New Haven, CT 06511 (“LICENSEE”) is effective as of the THIRD AMENDMENT EFFECTIVE DATE.
